Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 183.21%89.73K | 11.39%63.24K | 7.85%59.67K | -52.98%168.15K | -83.03%24.37K | -38.91%31.68K | -48.20%56.77K | 5.41%55.32K | 166.38%357.6K | 434.61%143.66K |
| Selling and administrative expenses | 170.28%27.75K | 49.75%41.82K | 14.22%36.83K | -51.39%78.39K | -88.24%7.96K | -72.40%10.27K | 1.27%27.93K | 11.69%32.24K | 119.12%161.27K | 314.24%67.63K |
| -General and administrative expense | 170.28%27.75K | 49.75%41.82K | 14.22%36.83K | -51.39%78.39K | -88.24%7.96K | -72.40%10.27K | 1.27%27.93K | 11.69%32.24K | 119.12%161.27K | 314.24%67.63K |
| Research and development costs | ---- | ---- | ---- | -7.13%72.88K | -30.89%16.42K | 46.01%21.42K | -29.03%12.13K | -0.21%22.92K | 125.56%78.47K | 125.24%23.75K |
| Other operating expenses | 189.41%61.98K | -25.75%21.41K | -1.05%22.84K | -54.28%89.76K | -78.41%16.42K | 46.01%21.42K | -64.83%28.84K | -2.28%23.08K | 223.74%196.33K | 620.95%76.03K |
| Operating profit | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.98%-168.15K | 83.03%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -166.38%-357.6K | -434.61%-143.66K |
| Net non-operating interest income (expenses) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating interest income | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Other net income (expenses) | 6K | |||||||||
| Other non-operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --6K | ---- |
| Income before tax | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Net income continuous operations | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -183.21%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.91%-31.68K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Diluted earnings per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -267.51%-0.01 | -1,037.90%-0.0061 |
| Basic earnings per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -267.51%-0.01 | -1,029.42%-0.0061 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.